Tuberculosis is one the leading causes of death globally and was before the COVID-19 pandemic the leading cause of death from a single infectious agent. Developing active tuberculosis is life threatening and therefore is the rise of drug-resistant tuberculosis alarming as this risk causing current treatments to become ineffective. Linezolid is a promising drug for treatment of drug-resistant pulmonary tuberculosis, but the effect of linezolid treatment for pulmonary tuberculosis subjects is still not understood well enough and the World Health Organization has requested this knowledge gap to be filled. In this project we support the closing of this knowledge gap by describing the pharmacokinetics of linezolid for treatment of pulmonary tuberculosis using data collected from a phase two clinical trial in a South African population. This was done by creating a pop-PK model and resulted in the PK of linezolid in pulmonary tuberculosis patients from South Africa was best described using a one-compartment model, with first-order absorption process preceded by a series of transit compartments and saturable elimination. However, the diagnostics of the model still show that there are room for improvements and future work is necessary to further optimize the model.